Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Doctors say the situation forces them to get creative in treating patients, but there’s hope that prices may fall more in the ...

Under the deal, cash-paying patients can access a month's supply of Wegovy through the Danish drugmaker's Novocare pharmacy ...

Novo Nordisk said Monday it will end its collaboration with Hims & Hers that offered the weight loss medication Wegovy for ...

Novo Nordisk ended a short-lived agreement to sell its Wegovy weight-loss drug through Hims & Hers Health on Monday, sending ...

A federal judge has rejected a bid by compounding pharmacies to allow them to continue making copies of Novo Nordisk's blockbuster weight-loss drugs Ozempic and Wegovy, upholding the U.S. Food and ...

A federal judge on Wednesday ruled that the Food and Drug Administration’s (FDA) decision to remove popular GLP-1s from its drug shortage list, ending the sale of compounded versions of the ...

For more than two years, drugs administered under the brand names Ozempic, which treats diabetes, and Wegovy, sold for obesity, were on the Food and Drug Administration’s list of drugs in short ...

Through June 30, self-paying patients who are new to Wegovy can obtain their first month of medicine for $199. After that, a month’s supply (28 days of 2.4 mg doses) will cost $499, according to ...

Pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, says its CEO is stepping down. The Danish company is citing a steep decline in the company’s share price.

Other factors can affect access. This week, CVS Health said Wegovy will become the preferred option on its standard formulary, or list of covered drugs, as of July 1. Zepbound will be excluded.

Tirzepatide and semaglutide were removed recently from a list of drug shortages by the U.S. Food and Drug Administration. Both manufacturers recently released programs that cut costs to about $500 ...